Welcome to our dedicated page for BridgeBio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on BridgeBio Pharma stock.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) is a pioneering commercial-stage biopharmaceutical company that specializes in the discovery, creation, and delivery of transformative medicines for patients suffering from genetic diseases and cancers with clear genetic drivers. Established in 2015, the company is headquartered in Palo Alto, California. BridgeBio's mission is to address significant unmet medical needs through genetic medicine by leveraging a comprehensive pipeline of development programs that span from early-stage scientific research to late-stage clinical trials.
The company's core focus areas include Mendelian diseases, Genetic Dermatology, Oncology, and Gene Therapy. BridgeBio’s innovative approach involves systematically mapping the genetic disease landscape to identify promising therapeutic assets. Their proprietary platform and management expertise are harnessed to accelerate the development of these early-stage assets into clinically impactful treatments.
BridgeBio’s robust pipeline boasts several notable programs:
- Acoramidis (AG10): Aiming to treat transthyretin amyloid cardiomyopathy (ATTR-CM), this next-generation, orally-administered TTR stabilizer has shown positive results in the Phase 3 ATTRibute-CM trial. The New Drug Application (NDA) for acoramidis has been accepted by the FDA, with a target decision date set for November 29, 2024.
- Infigratinib: Targeting achondroplasia and hypochondroplasia, this FGFR1-3 inhibitor aims to address skeletal dysplasias. The PROPEL 2 Phase 2 trial has demonstrated significant and sustained increases in growth velocity.
- BBP-418: Designed for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), this glycosylation substrate is under Phase 3 trials, with the potential for accelerated approval based on recent interactions with the FDA.
BridgeBio's track record includes successful capital raises, strategic partnerships, and a series of public offerings that have strengthened its financial positioning. The company recently completed a $200 million private financing for its oncology subsidiary, BridgeBio Oncology Therapeutics, to accelerate the development of its precision oncology pipeline.
Key recent developments include:
- The initiation of a comprehensive equity grants program to attract top talent in the biopharmaceutical industry.
- Positive results from multiple clinical trials, including significant improvements in health-related quality of life measures for patients with ATTR-CM treated with acoramidis.
- Ongoing collaborations with global pharmaceutical leaders like Bayer for the commercial development and distribution of key assets in international markets.
BridgeBio remains committed to advancing genetic medicine and delivering groundbreaking therapies to improve patient lives. For more information, visit bridgebio.com and follow them on LinkedIn and Twitter.
BridgeBio Pharma (Nasdaq: BBIO) has partnered with UC Berkeley's Bakar Labs to foster innovation in genetic disease and cancer treatments. This collaboration will support up to 50 startups, leveraging world-class facilities and expertise. CEO Neil Kumar sees the partnership as a way to strengthen the Bay Area biotech ecosystem and expedite the clinical development of new therapies. Bakar Labs aims to facilitate groundbreaking research and shared resources for entrepreneurs, enhancing progress in potential therapies for genetically-driven conditions.
BridgeBio Pharma (Nasdaq: BBIO) announced a collaboration with Baylor College of Medicine on July 21, 2022, to develop therapies for genetic diseases. This partnership aims to leverage Baylor's research capabilities and BridgeBio's drug development expertise to translate innovative findings into practical treatments for patients with unmet medical needs. The collaboration underscores BridgeBio's commitment to fostering meaningful academic partnerships in the biopharmaceutical industry.
BridgeBio Pharma (BBIO) announced positive Phase 1 data for BBP-711, a novel oral therapy aimed at treating primary hyperoxaluria type 1 (PH1) and recurrent kidney stone formation. Results indicated near complete inhibition of glycolate oxidase, significantly increasing plasma glycolate levels. Following its promising tolerability and efficacy, BridgeBio plans to initiate a pivotal Phase 2/3 study by the end of 2022, as well as a Phase 2 study targeting adult recurrent kidney stone formers, which impacts 1.5 million individuals in the U.S. and EU.
BridgeBio Pharma announced promising results from the Phase 1/2 clinical trial of BBP-812, a gene therapy for Canavan disease. Initial data from two participants revealed significant decreases in N-acetylaspartate (NAA) levels in the brain and urine, indicating the therapy may effectively target disease markers. With no serious adverse events reported, the trial is progressing well. If successful, BBP-812 could be the first treatment option for this ultra-rare, fatal condition affecting approximately 1,000 children in the U.S. and EU.
BridgeBio Pharma announced positive Phase 2b results for encaleret, targeting autosomal dominant hypocalcemia type 1 (ADH1). By day 5 of treatment, participants showed restored normal calcium homeostasis, with 92% achieving normal trough blood calcium levels. The company is scheduling a Phase 3 study to commence in 2022, assessing encaleret against standard care. The results are presented at ENDO 2022, and an investor call is scheduled for June 13, 2022, to discuss findings and future plans.
BridgeBio Pharma (Nasdaq: BBIO) and Venthera, Inc. presented preliminary data from the Phase 1b trial of VT30 topical gel, targeting venous and lymphatic lesions. The trial showed that VT30 was generally well-tolerated across 15 participants, with mild to moderate local rashes as the only notable adverse effect. Importantly, pharmacokinetic data indicated drug concentrations were sufficient within lesions, while no systemic drug was detected in plasma. Venthera plans to advance the 0.6% gel into further studies and is seeking development partners.
BridgeBio Pharma (BBIO) announced that preliminary data from a 24-week Phase 2b study of encaleret in treating autosomal dominant hypocalcemia type 1 (ADH1) will be presented at the Endocrine Society's Annual Conference on June 13, 2022. This data suggests that encaleret restores mineral homeostasis, marking a significant step in clinical research. Alongside this, comprehensive presentations on various programs, including achondroplasia and congenital adrenal hyperplasia, will also be discussed. An investor call is slated for the same day to focus on the Phase 2b data.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced participation in two key investor conferences. The Jefferies Healthcare Conference is scheduled for June 9 at 4:00 pm ET, followed by the Goldman Sachs Global Healthcare Conference on June 15 at 5:00 pm ET.
Live webcasts will be available on the BridgeBio Investors page. A replay will be accessible for 90 days post-event. Founded in 2015, BridgeBio focuses on developing transformative medicines targeting genetic diseases and cancers.
BridgeBio Pharma announced promising interim Phase 1 data for BBP-671, an investigational therapy targeting pantothenate kinase-associated neurodegeneration (PKAN) and organic acidemias. The study found BBP-671 in healthy volunteer plasma and cerebrospinal fluid, indicating its ability to cross the blood-brain barrier. Additionally, it elevated whole blood acetyl-CoA levels, demonstrating proof of mechanism. The company plans to advance to the next study phase for propionic acidemia and methylmalonic acidemia in late 2022 and initiate a pivotal study for PKAN in 2023.
BridgeBio Pharma, Inc. (BBIO) announced positive results from a Phase 2 trial of PTR-01, a recombinant collagen 7 protein replacement therapy for recessive dystrophic epidermolysis bullosa (RDEB). The treatment demonstrated rapid and consistent wound healing, with over 80% of wounds showing a significant reduction in size. Patients reported a 36% mean reduction in pain, and the therapy was well-tolerated over four months. The findings were presented at the Society for Investigative Dermatology Annual Meeting. Phoenix Tissue Repair has commenced a Phase 2 extension study for further evaluation.
FAQ
What is the current stock price of BridgeBio Pharma (BBIO)?
What is the market cap of BridgeBio Pharma (BBIO)?
What does BridgeBio Pharma, Inc. specialize in?
What are the core focus areas of BridgeBio Pharma's pipeline?
What are some key programs in BridgeBio's pipeline?
What recent financial achievements has BridgeBio Pharma accomplished?
Has BridgeBio Pharma formed any significant partnerships?
What recent clinical trial results has BridgeBio Pharma announced?
When was BridgeBio Pharma founded?
Where is BridgeBio Pharma headquartered?
What is the therapeutic approach of BridgeBio Pharma?
How can I learn more about BridgeBio Pharma’s developments?
